ライフサイエンスコーパス: menarche

1 ere not significantly associated with age of menarche.

2 ploratory analyses (n = 113) examined age at menarche.

3 data among participants who had not reached menarche.

4 g cellular differentiation and the timing of menarche.

5 amin D deficiency is associated with earlier menarche.

6 sun exposure, is inversely related to age at menarche.

7 ne of the fastest rates of decline in age at menarche.

8 eriodically about the occurrence and date of menarche.

9 sis of self-reported Tanner stage and age at menarche.

10 locus in regulating height and the timing of menarche.

11 gain, may be associated with earlier age at menarche.

12 dult BMI was robust to adjustment for age at menarche.

13 ion of genetic influences on CD by timing of menarche.

14 of etiological moderation of CD by timing of menarche.

15 ohorts, despite stability in the mean age at menarche.

16 on between growth, adiposity, and the age at menarche.

17 gkin's lymphoma associated with later age at menarche.

18 these differences did not emerge until after menarche.

19 , total cholesterol, and (in females) age at menarche.

20 risk factors, such as ages at menopause and menarche.

21 , sucrose, fructose, and aspartame and early menarche.

22 hood is associated with higher risk of early menarche.

23 intakes were associated with a later age at menarche.

24 ere positively associated with risk of early menarche.

25 nger among women who had been exposed before menarche.

26 s at 106 genomic loci associated with age at menarche.

27 , used a lactation suppressant, or had early menarche.

28 60) were more likely to have an older age at menarche (13.5, 12.5, and 12.6 years, respectively, P <

29 s conducted in women more than 2 years after menarche (177 lamotrigine, (HA) 186 valproate) to exclud

30 llele was associated with 0.12 years earlier menarche (95% CI = 0.08-0.16; P = 2.8 x 10(-10); combine

31 heritance of CYP3A4*1B correlates with early menarche, a breast cancer risk factor.

32 bertal timing variants associate with age at menarche, a late manifestation of puberty, and body mass

33 ependent signals (P < 5 x 10(-8)) for age at menarche, a milestone in female pubertal development.

34 ast composition at Tanner stage 4 and age at menarche.A total of 515 Chilean girls are included in th

35 e smoke exposure had an adjusted mean age at menarche about 4 months earlier than those unexposed.

36 d be emphasized when addressing early age at menarche across cultures.

37 nt for smoking, physical activity and age at menarche, after exclusion of 3% of females with the high

38 d soft drinks and early menarche (defined as menarche age <11 y).

39 were particularly marked in women with early menarche (age <12.5 years).

40 Associations were similar for race, age at menarche, age at first birth, family history, alcohol co

41 psy, body mass index at age 18 years, age at menarche, age at first birth, oral contraceptive use, bi

42 rnal self-reported age at conception, age at menarche, age at first birth, parity, and gravidity.

43 east disease, height at age 25 years, age at menarche, age at menopause, age at first birth, and pari

44 uthors investigated secular trends in age at menarche, age at menopause, and reproductive life span w

45 Breast cancer risks associated with age at menarche, age at menopause, breastfeeding, age at first

46 In analyses that adjusted for age, age at menarche, age at menopause, estrogen use, parity, body m

47 Subgroup analyses by age, age at menarche, age at menopause, menopausal status, number of

48 , oral contraceptive use or duration, age at menarche, age at menopause, or history of hysterectomy o

49 include inherited genetic mutations, age of menarche, age of menopause, and parity.

50 Compared to those with menarche aged <14, the age-adjusted odds ratios for HSV-

51 ), 0.71 (0.57-0.89) and 0.69 (0.54-0.89) for menarche aged 14, 15 and 16+ respectively.

52 iations between the selected SNPs and age at menarche (ages 9-17 years) using linear regression model

53 5% confidence interval: 1.12, 4.40) of early menarche among daughters of mothers who were single pare

54 Age at menarche among women with MS was generally lower than th

55 Women with type 1 diabetes have a delayed menarche and a greater prevalence of menstrual disorders

56 only the inverse association between age at menarche and adult BMI remained.

57 , after excluding those that had not started menarche and after excluding those using hormonal contra

58 rs conclude that the interval between age at menarche and age at first birth is associated with the r

59 Age at menarche and age at natural menopause are associated wit

60 height was positively associated with age at menarche and breast cancer.

61 nd no evidence of association between age at menarche and death from all cardiovascular diseases or s

62 An inverse association between age at menarche and death from IHD was observed only among nons

63 her reports of an association between age at menarche and fibroid development (regardless of characte

64 used to estimate associations between age at menarche and fibroid status and to test for interactions

65 Ages at menarche and first birth are established risk factors fo

66 terval of > or =16 years between the ages of menarche and first birth had 1.5-fold (95% confidence in

67 3% increase per pack-year of smoking between menarche and first childbirth (relative risk = 1.03, 95%

68 is associated with a short interval between menarche and first sexual intercourse (FSI).

69 The mean age of menarche and FSI was 12.4 and 16.0 years, respectively.

70 A short interval between menarche and FSI was a risk factor for cytologic abnorma

71 16/18 vaccine had nonmissing data for age of menarche and FSI.

72 ed to examine the association between age at menarche and gestational diabetes mellitus (GDM).

73 and two genetic risk scores, GRS1 for age at menarche and GRS2 for age at menopause.

74 Earlier menarche and irregular periods, among other markers of s

75 can exhibit acute pelvic pain shortly after menarche and may show non-specific and variable symptoms

76 djusted relative risks (RRs) associated with menarche and menopause for breast cancer overall, and by

77 Menarche and menopause mark the onset and cessation, res

78 The effects of menarche and menopause on breast cancer risk might not b

79 ual and reproductive features, e.g., ages at menarche and menopause, are found to be associated with

80 ximately 50% of the variation in both age at menarche and menopause, but to date the known genes expl

81 ed with reproductive traits, such as ages of menarche and menopause, in women of European ancestry.

82 no association between prognosis and age at menarche and menopause, menopausal status at diagnosis,

83 ions of female reproductive factors (ages at menarche and menopause, menopausal status, use of oral c

84 survival of variables related to pregnancy, menarche and menopause, prior use of exogenous hormones,

85 served an inverse association between age at menarche and MS risk.

86 ssed the possible association between age at menarche and multiple sclerosis (MS), and results are co

87 The observed associations with age at menarche and oral contraceptive use warrant further inve

88 which has been recently implicated in age of menarche and other phenotypes.

89 Age at menarche and other reproductive factors were not associa

90 uggest complex genetic relationships between menarche and overall obesity, and to a lesser extent cen

91 did not observe interactions between age at menarche and race.

92 method using the relationship between age at menarche and risk of breast cancer, with body mass index

93 Associations between age at menarche and risk of MS were evaluated with hazard ratio

94 investigated the association between age at menarche and risk of type 2 diabetes mellitus (T2DM) amo

95 e is known about associations between age at menarche and sexually transmitted infections, although g

96 e the role of early-life exposures in age at menarche and subsequent GDM risk.

97 erty was measured on the basis of the age at menarche and Tanner stage for pubic-hair and breast deve

98 ce, rather than a determinant, of the age at menarche and that secular changes in BMI and in the mean

99 Associations between breast cancer and early menarche and those with reproductive milestones in adult

100 od BMI seems to contribute to earlier age at menarche and, because of tracking, greater adult BMI and

101 interpretations of the impact of precocious menarche and, to a lesser extent, delayed menarche on CD

102 including parity, age at first birth, age at menarche, and age at menopause) with risk of colorectal

103 contraceptive use, cigarette smoking, age at menarche, and diabetes were associated with type I and t

104 e analysis of documented infertility, age at menarche, and family history did not show allelic associ

105 4-1.057; p<0.0001) for every year younger at menarche, and independently by a smaller amount (1.029,

106 MEM38B, ZNF483, NFAT5 and OLFM2) with age at menarche, and of two loci (MCM8 and BRSK1/TMEM150B) with

107 waist-to-hip ratio, body mass index, age at menarche, and parity in conditional logistic model].

108 Higher premenarcheal BMI predicted earlier menarche, and the strong association between premenarche

109 Early age at menarche appears to be associated with an increased risk

110 comprehensive genome-wide studies of age at menarche are lacking for AA women.

111 t past, such as age at first birth or age at menarche, are less predictive of late-life breast cancer

112 dence interval, 1.22-1.31; P<0.0001) and for menarche at >/=17 years of age was 1.23 (95% confidence

113 ears, the adjusted relative risk for CHD for menarche at </=10 years of age was 1.27 (95% confidence

114 arche (<12 years of age), those who reported menarche at 12-13 years of age or at 14 years of age or

115 Compared with women with menarche at 13 years, the adjusted relative risk for CHD

116 Compared with women with menarche at age 13 years, women who had their first mens

117 che (at <12 years of age) versus "not early" menarche (at >/= 12 years of age) (pooled hazard ratio =

118 m all causes for women who experienced early menarche (at <12 years of age) versus "not early" menarc

119 Seven percent underwent menarche before 11 years of age and 11% at 15 years or l

120 rity (90.7%) of girls in our cohort attained menarche before the data analyses with a mean +/- SD age

121 risk was U shaped, with both early and late menarche being associated with increased risk.

122 han 100 loci have been identified for age at menarche by genome-wide association studies; however, co

123 and EGR-1 acts with NAB proteins to initiate menarche by regulating the transcription of the luteiniz

124 Relative risks of T2DM across age-at-menarche categories (< or =11, 12, 13, 14, and > or =15

125 an adult height above the average for their menarche category are at particularly increased risk of

126 ly 7.4% of the population variance in age at menarche, corresponding to approximately 25% of the esti

127 ecular changes in BMI and in the mean age at menarche could be independent phenomena.

128 1-2 y until age 21-25 y; pubertal status and menarche data were collected.

129 After adjusting for maternal age at menarche, daughter's age, and body mass index at baselin

130 The mean age at menarche decreased by approximately 6 months for those b

131 9-1946, 1947-1964, and 1965-1983) and age at menarche (defined as < or =11.9 y, 12.0-13.1 y, and > or

132 artificially sweetened soft drinks and early menarche (defined as menarche age <11 y).

133 rls assigned to composites had lower risk of menarche during follow-up (hazard ratio = 0.57, 95% CI 0

134 rls in the vitamin D-deficient group reached menarche during follow-up compared with 23% of girls in

135 with higher serum FSH levels, earlier age at menarche, earlier age at first child, higher lifetime pa

136 the heritability of body mass index, age at menarche, educational attainment and smoking behavior.

137 )/height (m)(2)) on the probability of early menarche, estimates and standard errors from an automate

138 to 1 year was associated with earlier age at menarche even after adjustment for later childhood growt

139 ody size changes were associated with age at menarche even after considering later childhood body siz

140 cycles that regularized within 2 years after menarche, fecundability ratios for cycles that regulariz

141 ely examined the relationship between age at menarche, fibroid characteristics, and race.

142 Age at menarche, first and last live birth, and menopause; numb

143 er of reproductive years (subtracting age at menarche from age at natural menopause), from 36.1 years

144 vely) after adjustment for age, race, age at menarche, gamma-tocopherol, beta-carotene, total cholest

145 agnosed in 11% (n = 70) of women with age at menarche greater than or equal to 13 years compared with

146 In both menarche groups, TCDD levels were associated with decrea

147 with those who had an average-to-late age at menarche (>/= 11 years).

148 f menarche, those with FSI within 3 years of menarche had a greater risk of cytologic abnormalities (

149 Early age at menarche had a similar positive association in individua

150 thern Malawi we show that those with earlier menarche had earlier sexual debut, earlier marriage and

151 mmon genetic variants associated with age at menarche has a potential value in pointing to the geneti

152 Early menarche has been associated with increased risk of coro

153 Age at menarche has been associated with several reproductive c

154 Early menarche has been linked to risk of several chronic dise

155 The observed age of menarche has fallen, which may have important adverse so

156 for menstrual cycle regularity shortly after menarche, having a cessation of menstruation, use of ano

157 4-DCP) were inversely associated with age of menarche [hazard ratios of 1.10; 95% confidence interval

158 odifiable factors were included: age, age at menarche, height, a combination of parity and age at fir

159 M occurs almost exclusively in females after menarche, highlighting the central but as yet poorly und

160 en presence of cysts and tobacco use, age at menarche, history of pregnancy, or estrogen-containing m

161 Late age at menarche, hormone replacement therapy use, and Hispanic

162 s parity, age at first birth, breastfeeding, menarche, hormone replacement therapy use, somatotype at

163 nt genome-wide association studies of age at menarche identified several obesity-related variants.

164 ongest (67%) in girls with average timing of menarche (ie, age 12-13 years) and substantially weaker

165 tion data to detect genes influencing age at menarche in 17,510 women.

166 t a genome-wide association study for age at menarche in 4,714 women and report an association in LIN

167 ife and socioeconomic environment and age at menarche in 523 girls.

168 -nucleotide polymorphisms (SNPs) with age at menarche in 92,116 women of European descent from 38 stu

169 se, and hypertensive disease risks by age at menarche in a large prospective study of UK women.

170 tween vitamin D status and the occurrence of menarche in a prospective study in girls from Bogota, Co

171 was positively associated with risk of early menarche in a US cohort of African American and Caucasia

172 ained variants significantly associated with menarche in AA women.

173 tionship between EDC exposure and the age of menarche in adolescent girls.

174 sociated with a lower FGV and delayed age at menarche in Chilean girls.

175 l selection may have favored a higher age at menarche in females.

176 Age at menarche in girls, and age at spermarche in boys, did no

177 olescent obesity include earlier puberty and menarche in girls, type 2 diabetes and increased inciden

178 ge at puberty in the pig and loci for age at menarche in humans.

179 e environment and single parenting on age at menarche in Mexican Americans.

180 2,5-DCP, a potential EDC, and earlier age of menarche in the general U.S. population.

181 The estimated mean (+/-SE) ages at menarche in the same groups were 11.8 +/- 0.2 y and 12.6

182 d the role of psychosocial factors on age at menarche in this population.

183 rregular menstrual cycles and earlier age at menarche increased the risk of RA.

184 The impact of menarche interval on the odds of developing CIN2-3/AIS w

185 Other traits, such as age at menarche, IQ and lifespan, which have been changing duri

186 For girls treated before menarche, irradiation of the uterus and ovaries at doses

187 thors investigated the association of age at menarche, irregular periods, duration of menstruation, a

188 Age at menarche is a marker of timing of puberty in females.

189 Early menarche is a risk factor for cardiometabolic disease an

190 women of European ancestry (EA), and earlier menarche is a risk factor for obesity and type 2 diabete

191 It is unclear whether age at menarche is an independent determinant of future cardiov

192 These data suggest that early menarche is associated with increased risk of T2DM in ad

193 size changes are also associated with age at menarche is less clear.

194 These findings suggest that early menarche is only a risk marker.

195 ctive axis, is associated with risk of early menarche is sparse.

196 Risk is increased by early menarche, late menopause, and obesity in postmenopausal

197 I: 0.03, 0.80) and were more likely to start menarche later (>13 years) (odds ratio = 1.7, 95% CI: 0.

198 red with 12.6% (n = 57) of women with age at menarche less than 13 years (incidence rate per 100 pers

199 2 (P = 2.2 x 10(3)(3)), we identified 30 new menarche loci (all P < 5 x 10) and found suggestive evid

200 e, our results indicate that a proportion of menarche loci are important for pubertal initiation in b

201 t evidence of cross-ethnic generalization of menarche loci identified to date, and suggest a number o

202 tigation of SNPs in 42 previously identified menarche loci in EA women demonstrated that 25 (60%) of

203 yocardin-like 2 (MKL2) (P = 8.9 x 10(-9)), a menarche locus tagging a developmental pathway linking e

204 Age at menarche < or =10 years was associated with an increased

205 nificantly associated with an earlier age at menarche (< 11 years).

206 Compared with women who had an early age at menarche (<12 years of age), those who reported menarche

207 Our findings indicate that a young age at menarche may identify women at higher risk of GDM.

208 TCDD exposure, particularly exposure before menarche, may have enduring impacts on women's total thy

209 n smoking, hormonal use, diabetes and age at menarche/menopause was obtained for all individuals.

210 gnancy status, number of live births, age at menarche, menstrual irregularity, age at first birth, st

211 C6A/TACR3/PRKAG1) are associated with age at menarche (minor allele frequencies 0.08-4.6%; effect siz

212 ass (assumed to occur 2 years after onset of menarche) modified the association.

213 he extra vulnerability of girls with earlier menarche needs to be recognised.

214 sociations with ethnicity, education, age at menarche, number of livebirths, and oral contraceptive u

215 Incident early menarche occurred in 165 (8.3%) of the girls.

216 postmenopausal women who had an early age at menarche (odds ratio (OR) = 1.6, 95% confidence interval

217 Earlier age at menarche (odds ratio = 1.03, confidence interval: 1.01,

218 the data analyses with a mean +/- SD age at menarche of 11.9 +/- 0.7 y.

219 An independent effect of early menarche on adult adiposity cannot be excluded, but it i

220 African-American (AA) women have earlier menarche on average than women of European ancestry (EA)

221 us menarche and, to a lesser extent, delayed menarche on CD development.

222 ow an inverse direct causal effect of age at menarche on risk of breast cancer (independent of BMI),

223 ecular trend) and rate of maturation (age at menarche) on the timing and pattern of increases in body

224 ular, girls who consumed >125 g yogurt/d had menarche, on average, 4.6 mo (95% CI: 1.9, 7.4 mo) later

225 It presents soon after menarche or shows delayed presentation depending on the

226 Early age at menarche, oral contraceptive use, early age at menopause

227 seen with parity/age at first birth, age at menarche, oral contraceptive use, family history of brea

228 Age at menarche, oral contraceptive use, pregnancy, parity, age

229 or postmenopausal obesity (P = 0.02), age at menarche (P = 0.05), age at first birth (P = 0.04), and

230 ociation was observed with increasing age at menarche (P for trend = 0.02) and increasing years of or

231 ation factor were also associated with early menarche (P heterogeneity < 0.0001), and in contrast to

232 ade (P heterogeneity = 0.02), younger age at menarche (P heterogeneity = 0.04), lower current body ma

233 (p.W275X) is associated with 1.25-year-later menarche (P=2.8 x 10(-11)), illustrating the utility of

234 n usually have progressive pelvic pain after menarche, palpable mass due to hemihaemato(metro)colpos

235 served no significant associations of age at menarche, parity, age at first birth, and exogenous horm

236 tablished environmental risk factors (age at menarche, parity, age at first birth, breastfeeding, men

237 Risk of BCC was not associated with age at menarche, parity, age at first birth, infertility, use o

238 otential risk factors, including age, age at menarche, parity, age at first birth, total lifetime his

239 hed BC risk (body mass index, height, age at menarche, parity, age at menopause, smoking, alcohol and

240 myomata was inversely associated with age at menarche, parity, and age at first birth and positively

241 Other factors, including smoking, age at menarche, parity, and body mass index, did not significa

242 Reproductive factors, including age at menarche, parity, breastfeeding, and age at menopause, w

243 icant associations were observed with age at menarche, parity, lactation, oral contraceptive use, or

244 No association was found between age at menarche, parity, oral contraceptive use, estrogen repla

245 e and other risk factors, age<or=10 years at menarche (pooled RR 2.1, 95% confidence interval [95% CI

246 sociated with hormonal milestones, including menarche, pregnancy, contraceptive use, menopause, and t

247 s well correlated with recalled body size at menarche (r = 0.61, p < 0.001), but with some evidence o

248 For each 1-year increase in age at menarche, risk of MS was reduced by 13% (hazard ratio =

249 was not significantly associated with early menarche (RR for 1 serving/d increment: 0.88; 95% CI: 0.

250 lso positively associated with risk of early menarche (RR for 1 serving/d increment: 1.43; 95% CI: 1.

251 s was associated with a higher risk of early menarche (RR for 1 serving/d increment: 1.47; 95% CI: 1.

252 distributions than Caucasians, such as later menarche, shorter stature, higher parity, earlier age at

253 imal radius BMD, according to the time since menarche, showed a highly significant effect of suppleme

254 Menarche signals were enriched in imprinted regions, wit

255 ses adjusted for energy, age, and time since menarche, significant correlations (P < 0.05) were as fo

256 al (body size, pregnancy weight gain, age at menarche, smoking) and birth (birth weight, birth length

257 tted infections, although girls with earlier menarche tend to have earlier sexual debut and school dr

258 Although girls with early menarche tended to have significantly higher BMIs than d

259 The event of menarche tends to coincide with girls' transitions from

260 cts of common early life exposures on age at menarche, the authors examined data collected in a follo

261 rls with data on prospective diet and age at menarche.The mean +/- SD breast FGV and percentage of fi

262 er BMIs than did girls with average or later menarche, these differences did not emerge until after m

263 th women who postponed FSI beyond 3 years of menarche, those with FSI within 3 years of menarche had

264 Age at menarche, time to menstrual regularization, and duration

265 uggest a number of novel biological links to menarche timing in AA women.

266 synthesis as biological processes related to menarche timing.

267 ysical activity over four prior age periods (menarche to 21 years and 22-34, 35-50, and 51-65 years).

268 tivity during the earliest prior age period (menarche to 21 years), 0.70 for ages 22-34 years, 0.78 f

269 , and total reproductive duration [time from menarche to menopause]) were self-reported at study base

270 In this cohort, the relation of age at menarche to vascular disease risk was U shaped, with bot

271 accuracy of recall for age and body size at menarche, usual cycle length during the first 2 years, a

272 The daughter's mean age at menarche varied little by maternal prenatal alcohol cons

273 The weighted mean age of menarche was 12.0 years of age.

274 Mean age at menarche was 12.9 years (standard deviation, 1.4).

275 development; the associated delay in age at menarche was 3.6 months.

276 After adjustment, the mean age at menarche was a few months earlier among girls whose moth

277 s showed that each 1-year increase in age at menarche was associated with a 3% lower relative risk of

278 Young age at menarche was associated with increased risk of T2DM afte

279 Younger age at menarche was associated with risk only in white women.

280 The incidence of menarche was compared between groups by using time-to-ev

281 Early menarche was consistently associated with higher risk of

282 A 1-year increase in age at menarche was inversely associated with fibroids (adjuste

283 A decline in the age at menarche was recently reported for US girls.

284 Age at menarche was reported at baseline in 2000 when women wer

285 The date of menarche was reported every 6 mo.

286 oportional hazards model, the probability of menarche was twice as high in vitamin D-deficient girls

287 The body mass index percentile at menarche was well correlated with recalled body size at

288 fference between age at menopause and age at menarche, was used as a proxy of duration of exposure to

289 For age at menarche, we identified ten associated SNPs (P = 1 x 10(

290 To identify loci for age at menarche, we performed a meta-analysis of 32 genome-wide

291 es that regularized 2-3 and >/=4 years after menarche were 0.90 (95% CI: 0.80, 1.02) and 0.89 (95% CI

292 Menarcheal status and age at menarche were assessed via the Pubertal Development Scal

293 iously reported to be associated with age at menarche were confirmed, but none of the central adiposi

294 Recalled and original age at menarche were highly correlated (r = 0.79, p < 0.001).

295 ciations of body mass index loci with age at menarche were identified, and 11 adiposity loci previous

296 magnitudes of these risks for early and late menarche were smaller than those for CHD.

297 childhood is correlated with earlier age at menarche; whether birth and infant body size changes are

298 height is positively correlated with age at menarche, which in turn is negatively associated with br

299 ome-wide association of self-reported age at menarche with common single-nucleotide polymorphisms (SN

300 girls were followed annually until 4 y after menarche (x+/- SD: 7.1 +/- 2.6 y).